What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2023
   Article
2. Direct Quantitative Immunochemical Analysis of Autoinducer Peptide IV for Diagnosing and StratifyingACS infectious diseases · 2022
   Article
3. Pulmonary Exacerbations in Pediatric Patients: Retrospective Study in a Portuguese Cystic Fibrosis Center.Children (Basel, Switzerland) · 2022
   Article
4. Limited evidence of patient-to-patient transmission of Staphylococcus aureus strains between children with cystic fibrosis, Queensland, Australia.PloS one · 2022
   Article
5. Curating and comparing 114 strain-specific genome-scale metabolic models of Staphylococcus aureus.NPJ systems biology and applications · 2021
   Review
6. Impairment in inflammasome signaling by the chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients results in an increase in inflammatory response.Cell death & disease · 2021
   Article
7. Signal Synthase-Type versus Catabolic Monooxygenases: Retracing 3-Hydroxylation of 2-Alkylquinolones and TheirApplied and environmental microbiology · 2021
   Article
8. Bacterial Interactions withMicroorganisms · 2021
   Review
9. The Lung Microbiome of Three Young Brazilian Patients With Cystic Fibrosis Colonized by Fungi.Frontiers in cellular and infection microbiology · 2020
   Article
10. A Malaysian ex-smoker with cough, breathlessness and nonresolving bronchospasm.Breathe (Sheffield, England) · 2019
    Article
11. Factors affecting the growth of infants diagnosed with cystic fibrosis by newborn screening.BMC pediatrics · 2019
    Article
12. Antimicrobial Treatment ofFrontiers in pharmacology · 2019
    Review

Corrections and comments

• Commented on by
  Rebound stridor in children with croup after nebulised adrenaline: does it really exist?2019
• Commented on by
  Gastro-oesophageal reflux is not a major cause of brief resolved unexplained events in infants.2019
• Commented on by
  Protracted bacterial bronchitis is a precursor for bronchiectasis in children: myth or maxim?2019
• Commented on by
  Asthma attacks in children are always preceded by poor asthma control: myth or maxim?2020
• Commented on by
  Treating acute severe asthma attacks in children: using aminophylline.2020
• Commented on by
  Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?2021
• Commented on by
  Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?2021
• Comment on
  Myths and maxims in paediatric respiratory medicine.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.